The Study
262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial
This study gave different doses of a new medicine to people trying to lose weight and compared them to people who got a sugar pill. It found that those who got the medicine lost more weight. But it doesn't prove the medicine is the only reason — maybe people who got it also tried harder to eat better.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested a new weekly shot called pemvidutide in people with extra weight to see if it helps them lose weight and feel healthier.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 569 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Losing 15% of body weight is a big deal — it can reverse obesity-related diseases like diabetes and heart disease, and lower cholesterol reduces heart attack risk.
- 2People who got the highest dose (2.4 mg) lost 15.6% of their body weight — that’s like losing 16 pounds if you weighed 100.
- 3Over half lost at least 15% of their weight, and nearly half no longer qualified as obese.
- 4Cholesterol and triglycerides also dropped sharply.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes
Year
2024
Authors
Louis J Aronne, M. SCOTT HARRIS, M. S. Roberts, John J. Suschak, Shaheen Tomah, Jonathan Kasper, Liang He, Jay Yang, J. P. Frías, Sarah K. Browne
Related Content
Claims (5)
In adults with overweight or obesity, a weekly injection of pemvidutide at 2.4 mg for 48 weeks resulted in nearly half of the participants achieving a body mass index below 30 kg/m², which is the clinical threshold for no longer being classified as obese.
In adults with overweight or obesity and at least one related health condition, a weekly injection of pemvidutide for 48 weeks resulted in an average weight loss of 15.6%, compared to 2.2% with a placebo. Over half of those receiving the treatment lost at least 15% of their body weight, and nearly half no longer met the clinical definition of obesity.
In adults with excess weight and high blood fats, a weekly injection of pemvidutide for 48 weeks lowers triglycerides, total cholesterol, and LDL cholesterol by specific percentages, even if body weight does not change.
In adults with overweight or obesity, taking weekly pemvidutide at doses up to 2.4 mg for 48 weeks is linked to only small increases in heart rate and no meaningful changes in blood sugar or HbA1c levels.
In adults with overweight or obesity, taking 2.4 mg of pemvidutide once a week leads to more weight loss than taking 1.2 mg or 1.8 mg weekly, suggesting that higher doses produce greater effects.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.